Trial Details
- Condition
Non-small cell lung cancer (NSCLC)
- Potential Treatment Under Study
Selpercatinib
The Study at a Glance
The LIBRETTO-432 Study is seeking participants who have been treated for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). The purpose of the study is to learn if an investigational medicine helps to prevent the return of NSCLC following standard treatment. People who are interested in participating can begin the screening process prior to completing their NSCLC treatment.
- Participation Length
Up to 3 years
- Appointments
About every 2 weeks
- Ages
18+
- Cancer Treatment Status
Have received treatment
What's Involved?
Who Qualifies?
Locations
Researchers in over 200 locations globally are looking for volunteers for this research study. The map below shows research sites currently open for enrollment in your region. New sites may be added at a later date.
You may be reimbursed for travel or study-related expenses. For more information, please click the I'm Interested button to be connected with a research site.
Why Participate?
If you qualify, you're the only person who can decide if participation is right for you. Each person and each research study are different. Every research study has risks and benefits to consider when deciding to participate.
Adults with a history of stage IB, II, IIIA non-small cell lung cancer may want to take part in this research study for the following reasons.
Advance Medicine
Support important research for NSCLC medicines and possibly help others like you.
Be Informed
Find out if your NSCLC is RET fusion-positive and if it may have other genes associated with cancer growth.
Explore Options
Possibly try Selpercatinib or maybe learn of other targeted therapies you could be a good candidate to receive.
